Advertising
COMMENT

It IPOs next week and is a cloud-based data warehousing company. Berkshire Hathaway and Salesforce will each buy $250 million of stock. The CEO has a great track record in Silicon Valley; Snowflake is the CEO's third company he's taken public. He sees a lot of demand in Snowflake, so should IPO well. He's conflicted, because the IPO may be too red hot and overbought. He'll know more about this company next week.

Technology
BUY
Terrific managers. Down 8% this year so it's a good time to add or enter.
investment companies / funds
DON'T BUY
A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.
Pharma & Healthcare
DON'T BUY
A tiny company and speculative. Some months ago, they had a tired, but profitable portfolio of generic and profitable drugs that produced a stream of cash. They invested that cash to treat droopy eyelid, with a goal to be a less-generic drug company and more branded. Then they tested an MS-related drug, but shelved it which hurt the stock. Two months, the FDA approved the droopy eyelid drug which pushed the stock higher. Then they made a secondary offering which didn't meet demand and the stock pulled back.
Pharma & Healthcare
BUY
Their speciality is IP phones and they have been doing well. Earnings will almost double from 4 cents to 8 cents, with further doubling in 2022. P/E is at 29x for 2021. If they are able to deliver it, the stock is attractively priced.
Telecommunications